Skip to content
Clinical Trials for Alzheimer's Disease

Maitland, Florida

Alzheimer's disease clinical trials in Maitland, FL

19 Alzheimer's disease studies are recruiting participants at sites in Maitland as of November 16, 2026, according to ClinicalTrials.gov. Clinical Trials for Alzheimer's Disease can help you understand your options and connect with a study team.

Call (888) 927-5895
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Maitland at a glance

  • 19 studies are recruiting at a site in Maitland.
  • By phase: Phase 1 (4), Phase 1/2 (1), Phase 2 (7), Phase 3 (6), Observational (1).
  • By sponsor: industry (19).
  • Most recent update to one of these records: November 16, 2026.

Studies recruiting in Maitland

Basic details from each study's public record. Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

    • Phase 3
    • Ages 50 to 90
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    K2 Medical Research, LLC
    Registry record
    NCT07177352 · updated
  2. Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

    • Phase 3
    • Ages 55 to 90
    • All sexes
    Sponsor
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company
    Study site
    K2 Medical Research - Maitland
    Registry record
    NCT05980949 · updated
  3. A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease

    • Phase 3
    • Ages 55 to 80
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    K2 Medical Research, LLC
    Registry record
    NCT07717411 · updated
  4. A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

    • Phase 2
    • Ages 55 to 85
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    K2 Medical Research ORLANDO
    Registry record
    NCT07589595 · updated
  5. A Study of LY3439539 in Participants With Alzheimer's Disease

    • Phase 1
    • Ages 50 to 85
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    K2 Medical Research
    Registry record
    NCT07598370 · updated
  6. A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease

    • Phase 2
    • Ages 55 and older
    • All sexes
    Sponsor
    Intra-Cellular Therapies, Inc.
    Study site
    K2 Medical Research
    Registry record
    NCT06540833 · updated
  7. A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia

    • Phase 2
    • Ages 55 and older
    • All sexes
    Sponsor
    Intra-Cellular Therapies, Inc.
    Study sites
    K2 Medical Research · Neurology Associates PA
    Registry record
    NCT06651567 · updated
  8. A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease

    • Phase 1
    • Ages 50 to 85
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    K2 Medical Research, LLC
    Registry record
    NCT06297590 · updated
  9. An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease

    • Phase 1
    • Ages 30 to 80
    • All sexes
    Sponsor
    Voyager Therapeutics
    Study site
    K2 Medical Research, LLC
    Registry record
    NCT07764146 · updated
  10. A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

    • Phase 3
    • Ages 55 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    K2 Medical Research ORLANDO
    Registry record
    NCT07602582 · updated
  11. [18F]PI-2620 Phase 3 Histopathological Study

    • Phase 3
    • Ages 50 and older
    • All sexes
    Sponsor
    Lantheus Biosciences Ltd.
    Study site
    K2 Medical Research
    Registry record
    NCT05641688 · updated
  12. A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

    • Phase 2
    • Ages 50 to 85
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    K2 Medical Research ( Site 1047)
    Registry record
    NCT07033494 · updated
  13. A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)

    • Phase 2
    • Ages 40 to 55
    • All sexes
    Sponsor
    Alnylam Pharmaceuticals
    Registry record
    NCT07636811 · updated
  14. Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

    • Phase 2
    • Ages 55 to 90
    • All sexes
    Sponsor
    Celgene
    Study site
    ClinCloud
    Registry record
    NCT06808984 · updated
  15. Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease

    • Phase 1/2
    • Ages 40 to 85
    • All sexes
    Sponsor
    NKGen Biotech, Inc.
    Study site
    K2 Medical Research
    Registry record
    NCT06189963 · updated
  16. A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)

    • Phase 3
    • Ages 55 to 90
    • All sexes
    Sponsor
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company
    Study site
    K2 Medical Research - Maitland
    Registry record
    NCT05511363 · updated
  17. A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)

    • Phase 1
    • Ages 45 to 85
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    K2 Medical Research
    Registry record
    NCT06657768 · updated
  18. Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia

    • Observational
    • Ages 60 to 90
    • All sexes
    Sponsor
    GAP Innovations, PBC
    Study site
    K2 Medical Research
    Registry record
    NCT06584357 · updated
  19. Open-label Extension Study in Participants With Early Alzheimer's Disease

    • Phase 2
    • Ages 50 to 85
    • All sexes
    Sponsor
    GlaxoSmithKline
    Study site
    GSK Investigational Site
    Registry record
    NCT07105709 · updated

Source: ClinicalTrials.gov. Data processed . See every Alzheimer's disease study recruiting in Maitland, FL on ClinicalTrials.gov.

Ask about studies near Maitland

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Florida

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Clinical Trials for Alzheimer's Disease does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-5895

or send a short form

How should we reach you?

Call